Dermavant: Posters Unveil Additional Data for Once-Daily Topical Tapinarof

Dermavant Sciences will present data in poster form from its two pivotal phase 3 trials for tapinarof for the treatment of psoriasis in adults, PSOARING 1 and PSOARING 2, at AAD VMX 2021. Tapinarof is a novel, once-daily therapeutic aryl hydrocarbon receptor modulating agent (TAMA).

The posters feature secondary efficacy endpoints and patient-reported outcomes data from patients with mild, moderate, or severe chronic plaque psoriasis after 12 weeks of treatment with tapinarof cream 1% dosed once daily compared to vehicle QD.

At Week 12, a significantly higher proportion of patients treated with tapinarof cream 1%, QD achieved PASI90 in PSOARING 1 (18.8%) and PSOARING 2 (20.9%) compared to patients treated with vehicle in PSOARING 1 (1.6%; P=0.0005) and PSOARING 2 (2.5%; P<0.0001).

A statistically significantly higher proportion of patients treated with tapinarof cream 1%, QD achieved at least a 4-point NRS improvement at each time point from Week 2 through Week 12. At Week 12 in PSOARING 1 and PSOARING 2, 67.5 percent and 59.7 percent respectively, of active treatment patients had a 4-point NRS improvement, compared to 46.1 percent and 31.3 percent, respectively, of patients receiving vehicle.

At Week 4, patients treated with tapinarof cream, 1% QD reported significant improvements in quality of life as measured by the DLQI.

“It is encouraging to see Phase 3 secondary endpoints data like this from a topical,” says Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System. “Seeing the PASI90 scores for approximately one in five patients in the PSOARING pivotal trials makes me extremely excited for what tapinarof may mean as a treatment option for patients with psoriasis, if approved.”

“Psoriasis is a chronic disease that can significantly interfere with all aspects of a patient’s daily life,” says Robert Bissonnette, MD, FRCPC, Chief Executive Officer and Medical Director at Innovaderm Research. “Tapinarof has demonstrated significant promise regarding some of the most problematic symptoms of this skin disease, including significantly reducing itch by at least four points on a 0 to 10 scale.”

The most commonly reported adverse events were folliculitis, nasopharyngitis, and contact dermatitis.